Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter TAnn Oncol 2008[Sep]; 19 (9): 1530-9Anthracycline-trastuzumab-containing regimens demonstrate significant clinical activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, the utility of this strategy is limited by unacceptably high rates of significant cardiotoxicity, particularly with concurrent administration. Anthracycline-induced cardiotoxicity is thought to be mediated primarily through increased myocardial oxidative stress, modified partly by the activity of neuregulins. Trastuzumab-induced cardiotoxicity is thought to be mediated by the ErbB/neuregulin system, with exposure to trastuzumab partly blocking the protective effect of neuregulins on the myocardium. As a result, trastuzumab increases the risk of anthracycline-induced cardiotoxicity. Several strategies have been adopted in attempts to minimize cardiotoxicity, including patient selection on the basis of preexisting cardiac risk, monitoring of cardiac function during treatment, and early management of cardiac dysfunction. The use of less cardiotoxic anthracyclines may be one strategy to lessen the risk of cardiotoxicity. Liposomal doxorubicin products offer similar efficacy compared with conventional doxorubicin, with significantly less cardiotoxicity, and have been successfully used in combination with trastuzumab in the metastatic and neo-adjuvant setting. Clinical trials are currently underway to assess the safety of pegylated liposomal doxorubicin during concurrent administration with trastuzumab compared with standard sequential treatment using conventional doxorubicin in the adjuvant setting.|Anthracyclines/*administration & dosage/adverse effects[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*administration & dosage/adverse effects[MESH]|Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects[MESH]|Breast Neoplasms/*drug therapy/genetics/mortality/pathology[MESH]|Cardiomyopathies/*chemically induced/*prevention & control[MESH]|Chemotherapy, Adjuvant[MESH]|Clinical Trials, Phase III as Topic[MESH]|Dose-Response Relationship, Drug[MESH]|Doxorubicin/administration & dosage/adverse effects[MESH]|Female[MESH]|Gene Expression Regulation, Neoplastic[MESH]|Heart Function Tests[MESH]|Humans[MESH]|Mastectomy/methods[MESH]|Maximum Tolerated Dose[MESH]|Neoplasm Staging[MESH]|Prognosis[MESH]|Randomized Controlled Trials as Topic[MESH]|Receptor, ErbB-2/genetics/*metabolism[MESH]|Risk Assessment[MESH]|Sensitivity and Specificity[MESH]|Survival Analysis[MESH]|Trastuzumab[MESH]|Treatment Outcome[MESH] |